Press releases
These press releases are intended for journalists and analysts/investors.
-
PROLIA® (denosumab) now approved for the treatment of osteoporosis in men
Amgen Australia and GlaxoSmithKline Australia (GSK) today announced the Therapeutic Goods Administration (TGA) has approved a new indication
-
Australian Medicine Icon is Back!
New Children’s Panadol® 1-5 Years Suspension Now on Shelf
-
GSK awards grant for Indigenous researcher at University of Melbourne
GlaxoSmithKline (GSK) Australia will award a capacity building grant to an Indigenous researcher from The University of Melbourne's School
-
Poppy Crop Security
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security from recent media reports in Tasmania
-
Tafinlar® (dabrafenib mesilate) registered for the treatment of metastatic melanoma in Australia
Tafinlar® (dabrafenib) has been approved by the Therapeutics Goods Administration (TGA) in Australia for the treatment of patients
-
Update to Rotarix prescribing information
GlaxoSmithKline Australia (GSK) has updated the prescribing information (PI) for Rotarix®, its rotavirus vaccine
-
GSK to Trial Poppy Growing in Victoria
GlaxoSmithKline (GSK) Australia announced today that small scientific trials of poppies, used as a source of medicinal alkaloids
-
Children’s Panadol® 1-5 Years Suspension temporarily out of stock
The makers of Children’s Panadol®, GSK, today confirmed that their Children’s Panadol® 1-5 years suspension range would be out of stock
-
Update on dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on Wednesday 17 July 2013 by the Federal Court to grant a temporary injunction
-
Dosing device in new Children’s Panadol 1-5 years suspension
GlaxoSmithKline (GSK) is disappointed with the decision made on May 28 2013 by the Federal Court (Justice Rares)
-
New GSK additions to the National Immunisation Program (NIP)
The addition of two new vaccines to the National Immunisation Program means that Australian children will now require two less injections
-
Changes to GSK Manufacturing Site in Melbourne
GlaxoSmithKline (GSK) Australia is intending to close the tablet packaging part of the business at the Melbourne site in Boronia
-
GSK Australia Reports 2012 Results to ASIC
GlaxoSmithKline (GSK) reported to the Australian Securities and Investment Commission (ASIC) for 2012 sales of $1,452m
-
GSK discloses 2012 payments to Australian healthcare professionals
As part GlaxoSmithKline’s (GSK) ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid
-
Fluarix® Product Notification
GlaxoSmithKline Australia (GSK) in consultation with the Therapeutic Goods Administration (TGA) has issued a product notification
-
GSK’s response to the public roundtable report on Arachnoiditis
GlaxoSmithKline (GSK) has reviewed the final report of the House of Representatives Standing Committee on Health and Ageing
-
Report on the Public roundtable into Adhesive Arachnoiditis
GlaxoSmithKline (GSK) welcomes the report on the roundtable into adhesive arachnoiditis provided by the Standing Committee
-
GSK Australia divestment of Kapanol Complete
GSK Australia’s divestment of the pain relief product Kapanol (morphine sulphate) to Mayne Pharma Group Limited (Mayne Pharma)
